|Other Names||Toll-interacting protein, TOLLIP|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2163c was selected from the Center region of human TOLLIP . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Component of the signaling pathway of IL-1 and Toll-like receptors. Inhibits cell activation by microbial products. Recruits IRAK1 to the IL-1 receptor complex. Inhibits IRAK1 phosphorylation and kinase activity (PubMed:11751856). Connects the ubiquitin pathway to autophagy by functioning as a ubiquitin- ATG8 family adapter and thus mediating autophagic clearance of ubiquitin conjugates. The TOLLIP-dependent selective autophagy pathway plays an important role in clearance of cytotoxic polyQ proteins aggregates (PubMed:25042851).|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The Toll/IL1R (TIR) domain is highly conserved in the cytoplasmic regions of several molecules associated with innate immunity. The deduced 274-amino acid human TOLLIP protein, which is 97% identical to the mouse sequence, features a type II C2 motif. TOLLIP binds to IL1RAP, to a complex of IL1RAP-IL1R1, and to IL18R. TOLLIP-IL1R-associated kinase-1 (IRAK1) complexes appear to exist constitutively. Furthermore, TOLLIP recruits IRAK to the IL1R complex. The TOLLIP-IRAK1 complex is terminated by stimulation with IL1B and IRAK phosphorylation. TOLLIP also interacts with TLR2 and TLR4; TOLLIP overexpression inhibits nuclear factor kappa-B (NFKB) activation in response to lipopolysaccharide and IL1B.
Zhang, G., et al., J. Biol. Chem. 277(9):7059-7065 (2002).Bulut, Y., et al., J. Immunol. 167(2):987-994 (2001).Burns, K., et al., Nat. Cell Biol. 2(6):346-351 (2000).Volpe, F., et al., FEBS Lett. 419(1):41-44 (1997).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.